Product Description
Since last manyyears Saintroy Lifescience is leading manufacture, export and supplierofTrastuzumab for Injection from Surat, Gujarat, India. Trastuzumab for Injection used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive.
Tags: Trastuzumab for Injection manufacturer, Trastuzumab for Injection exporter, Trastuzumab for Injection supplier,and Trastuzumab for Injection, whogmp approved Trastuzumab for Injection Manufacturerand supplier, Trastuzumab for Injection distributor, Trastuzumab ForInjection shipper, Trastuzumab for Injection 440 mgTrastuzumab for Injection440 mg supplier, Trastuzumab for Injection440 mg.
ISO/GMP/cGMP/WHOGMP/NAFDAC approved, PPB Kenya approved/USFDA approved/EUGMP approved/MOH Iran approved manufacturingfacility in Gujarat, India.
Registration: Saintroy Lifescience is interested in registrationof own brand or customer brands in ministry of health of clientscountry and we also provide the products samples, COA, COPP, ACTorCTD dossier, DMF, Manufacturing license, Free sales certificate and other required documents.
Export Country :Saintroy Lifescience Trastuzumab for Injectionexport to USA, Canada, Germany, Europe, France, Ghana, Nigeria,Kenya, Senegal, Sudan,UAE, Kuwait, Dubai, Cameroon, Lebanon, Peru, Chile,Somalia, Philippines, Myanmar, Maldives, Thailand, Singapore, Malaysia, HongKong, China, Zimbabwe, Togo, Burkina Faso, Niger,Guinea Bissau, Congo,Democratic of republic, Ivory Costa, Oman, Guatemala, Nicaragua, Salvador,Qatar, Costa Rica, Panama, Cuba, Colombia, Bolivia, Argentine, Algeria, Guyana,Morocco, Jordan, Bahrain, Iran, Egypt, Kyrgyzstan, Uzbekistan, Kazakhstan.
Mechanism of ActionTrastuzumab specifically binds to the HER2/neu receptor, blocking cellular proliferation in cancers overexpressing HER2. This targeted approach helps slow or halt the progression of certain forms of breast and gastric cancers, maximizing therapeutic benefits while minimizing off-target effects.
Preparation and AdministrationTo prepare, reconstitute each 150 mg vial with 7.2 ml of bacteriostatic water for injection. The drug must be stored in a cool, dry place and, once constituted, should be used within 28 days if refrigerated. Administration is via intravenous route under clinical supervision to ensure accurate dosing and patient monitoring.
Clinical Applications and BenefitsIndicated for patients with HER2-positive breast and metastatic gastric cancer, Trastuzumab offers a targeted treatment option. It is designed for use in hospitals and clinics, ensuring professional handling and monitoring for optimal patient safety and efficacy.
FAQ's of Trastuzumab For Injection:
Q: How should Trastuzumab for Injection be prepared for administration?
A: To prepare, reconstitute the lyophilized powder of each 150 mg vial with 7.2 ml of bacteriostatic water for injection. Mix gently until fully dissolved. The resulting solution should be stored refrigerated and used within 28 days.
Q: What are the recommended dosage and administration intervals for this medication?
A: The initial dose is 8 mg/kg administered intravenously. Subsequent doses are 6 mg/kg IV every three weeks, as directed by clinicians in a hospital or clinical setting.
Q: When should the reconstituted solution be discarded?
A: After reconstitution, if stored in a refrigerator, the solution must be used within 28 days. Any unused portion beyond this period should be discarded according to medical protocols.
Q: Where should Trastuzumab vials be stored before and after reconstitution?
A: Unopened vials should be kept in a cool, dry place in their original packaging. After reconstitution, the solution must be stored refrigerated and protected from light.
Q: What is the main benefit of using Trastuzumab for HER2-positive cancers?
A: Trastuzumab targets and binds HER2/neu receptors, effectively inhibiting cancer cell growth and proliferation in HER2-positive breast and metastatic gastric cancers, improving clinical outcomes.
Q: Is Trastuzumab suitable for use outside hospital or clinical environments?
A: No, this medication is intended exclusively for hospital and clinical use, ensuring appropriate preparation, administration, and patient monitoring by healthcare professionals.